Saram ConsultingGxP & AI Consulting for Life Sciences. Custom AI integrations, Part 11 compliance validation, and equity-based engineering partnerships for biotech.Explore Services at saram.io →
← Back to Home

Sellas Life Sciences Group

NASDAQ: SLS ↗$13.66 USD

Sellas Life Sciences Group is a late-stage immuno-oncology company developing peptide-based cancer vaccines and targeted small molecules. Its lead programme, galinpepimut-S, targets the WT1 antigen in acute myeloid leukemia and other WT1-expressing cancers.

Company Info

Sector:Immuno-Oncology
Headquarters:New York, NY, USA
Founded:2017

Clinical Development Pipeline

Galinpepimut-S (GPS)

Target: WT1 peptide vaccine
Maintenance therapy in acute myeloid leukemia
Preclinical
Phase 1
Phase 2
Phase 3
Approved

SLS009 (tambiciclib)

Target: CDK9
Relapsed or refractory acute myeloid leukemia
Preclinical
Phase 1
Phase 2
Phase 3
Approved

Recent News

Leadership Team

Careers & Job Openings

See all open roles

Clinical / Regulatory
New York, NY
Apply Now →